Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis-Reference-Cited by-同舟云学术

Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis

Published:2024-04-03 Issue:6 Volume:27 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Rao Sunyin¹,Min Li²,Zhao Jie¹,Su Juan³,Ye Lianhua¹

Affiliation:

1. Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China

2. Department of Respiratory Medicine, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650051, P.R. China

3. Department of Ultrasonic Diagnosis, People's Hospital of Yulong County, Lijiang, Yunnan 674199, P.R. China

Publisher

Spandidos Publications

Reference35 articles.

1. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

2. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial;Paz-Ares;Ann Oncol,2020

3. Durvalumab prescribing information;Food and Drug Administration

4. Nationwide real-life safety and treatment exposure data on durvalumab after concurrent chemoradiotherapy in unresectable stage III, locally advanced, non-small cell lung cancer: Analysis of patients enrolled in the French early access program;Avrillon;Lung,2022

5. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP);Faehling;Lung Cancer,2020